Passage Bio

Yahoo Finance • 5 months ago

PASSAGE BIO, INC. Q3 Loss Decreases, Beats Estimates

(RTTNews) - PASSAGE BIO, INC. (PASG) announced Loss for third quarter that decreased from the same period last year and beat the Street estimates. The company's bottom line totaled -$7.75 million, or -$2.44 per share. This compares with... Full story

Yahoo Finance • 5 months ago

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a high-productivity, susp... Full story

Yahoo Finance • 5 months ago

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D.... Full story

Yahoo Finance • 7 months ago

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will... Full story

Yahoo Finance • 8 months ago

Canaccord Genuity lowers Passage Bio stock price target to $67 from $260

Investing.com - Canaccord Genuity lowered its price target on Passage Bio Inc. (NASDAQ:PASG) to $67.00 from $260.00 on Thursday, while maintaining a Buy rating on the stock. Currently trading at $6.38, the stock sits well below analyst tar... Full story

Yahoo Finance • 8 months ago

Passage Bio GAAP EPS of -$2.96 beats by $1.08

* Passage Bio press release [https://seekingalpha.com/pr/20197173-passage-bio-reports-second-quarter-2025-financial-results-and-provides-recent-business] (NASDAQ:PASG [https://seekingalpha.com/symbol/PASG]): Q2 GAAP EPS of -$2.96 beats b... Full story

Yahoo Finance • 8 months ago

Lynx1 capital buys Passage Bio (PASG) shares worth $733,825

Lynx1 Capital Management L.P., a ten percent owner of Passage Bio, Inc. (NASDAQ:PASG), has increased its stake in the company through a series of purchases. According to a Form 4 filing with the Securities and Exchange Commission, the firm... Full story

Yahoo Finance • 9 months ago

Passage Bio Announces 1-for-20 Reverse Stock Split

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, tod... Full story

Yahoo Finance • last year

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will part... Full story

Yahoo Finance • 2 years ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it ha... Full story

Yahoo Finance • 2 years ago

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 2023 Expec... Full story

Yahoo Finance • 2 years ago

Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that... Full story

Yahoo Finance • 2 years ago

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it ha... Full story

Yahoo Finance • 3 years ago

Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that... Full story

Yahoo Finance • 3 years ago

Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award

PHILADELPHIA, May 04, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, has announced Nicolett... Full story

Yahoo Finance • 3 years ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, April 21, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it h... Full story

Yahoo Finance • 3 years ago

Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that... Full story

Yahoo Finance • 3 years ago

Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

PHILADELPHIA, March 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that... Full story

Yahoo Finance • 3 years ago

Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

Presented additional interim data at 19th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial safety and biomarker data from Cohort 4 e... Full story

Yahoo Finance • 3 years ago

Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program

$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or universityScholarship application deadline is April 1 for the initial award in the fall of 2023 PHILADELPHI... Full story